4SC Past Earnings Performance
Past criteria checks 0/6
4SC's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 16.9% annually. Revenues have been growing at an average rate of 6.5% per year.
Key information
-2.6%
Earnings growth rate
11.6%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 6.5% |
| Return on equity | -108.1% |
| Net Margin | -3,293.8% |
| Next Earnings Update | 10 Aug 2023 |
Recent past performance updates
Recent updates
Companies Like 4SC (ETR:VSCA) Could Be Quite Risky
Jan 15
We Think 4SC (ETR:VSCA) Can Afford To Drive Business Growth
Aug 04We're Not Very Worried About 4SC's (ETR:VSCA) Cash Burn Rate
Feb 13We Think 4SC (ETR:VSCA) Can Afford To Drive Business Growth
Aug 27We Think 4SC (ETR:VSC) Can Afford To Drive Business Growth
Feb 22Our Take On 4SC's (ETR:VSC) CEO Salary
Dec 30
Revenue & Expenses BreakdownBeta
How 4SC makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 22 | 0 | -14 | 4 | 0 |
| 30 Sep 22 | 0 | -19 | 4 | 0 |
| 30 Jun 22 | 0 | -23 | 3 | 20 |
| 31 Mar 22 | 7 | -17 | 3 | 20 |
| 31 Dec 21 | 14 | -10 | 5 | 0 |
| 30 Sep 21 | 15 | -8 | 4 | 5 |
| 30 Jun 21 | 16 | -7 | 4 | 9 |
| 31 Mar 21 | 9 | -13 | 3 | 14 |
| 31 Dec 20 | 2 | -19 | 3 | 18 |
| 30 Sep 20 | 1 | -19 | 3 | 17 |
| 30 Jun 20 | 0 | -19 | 3 | 16 |
| 31 Mar 20 | 1 | -16 | 3 | 15 |
| 31 Dec 19 | 2 | -14 | 3 | 14 |
| 30 Sep 19 | 2 | -15 | 3 | 15 |
| 30 Jun 19 | 2 | -17 | 3 | 16 |
| 31 Mar 19 | 3 | -17 | 3 | 17 |
| 31 Dec 18 | 4 | -18 | 3 | 18 |
| 30 Sep 18 | 6 | -15 | 3 | 17 |
| 30 Jun 18 | 7 | -12 | 3 | 15 |
| 31 Mar 18 | 6 | -11 | 3 | 13 |
| 31 Dec 17 | 4 | -11 | 3 | 11 |
| 30 Jun 17 | 2 | -10 | 3 | 9 |
| 31 Mar 17 | 2 | -11 | 4 | 10 |
| 31 Dec 16 | 2 | -11 | 4 | 11 |
| 30 Jun 16 | 1 | -11 | 4 | 9 |
Quality Earnings: VSCA is currently unprofitable.
Growing Profit Margin: VSCA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VSCA is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.
Accelerating Growth: Unable to compare VSCA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VSCA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-26.8%).
Return on Equity
High ROE: VSCA has a negative Return on Equity (-108.07%), as it is currently unprofitable.